Research and nonresearch industry payments to nephrologists in the United States between 2014 and 2021

A Murayama, S Kamamoto, H Kugo… - Journal of the …, 2023 - journals.lww.com
Background Financial relationships between nephrologists and the health care industry have
been a concern in the United States over the past decade. Methods To evaluate industry …

[HTML][HTML] Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies …

A Murayama, S Kamamoto, H Saito, A Ozaki - Scientific Reports, 2023 - nature.com
There are prevalent financial relationships between dermatologists and pharmaceutical
companies in Japan. However, little was known about the extent of whole picture of the personal …

Evaluation of financial conflicts of interest and quality of evidence in Japanese gastroenterology clinical practice guidelines

A Murayama, S Kamamoto, N Murata… - Journal of …, 2023 - Wiley Online Library
Sae Kamamoto: Study concept and design, data collection, statistical analysis, visualization,
and … Anju Murayama and Sae Kamamoto had full access to all study data. All authors take …

[HTML][HTML] Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 …

E Kusumi, A Murayama, S Kamamoto… - Blood Cancer …, 2022 - nature.com
Collaboration between healthcare professionals, patients, and pharmaceutical companies
have helped development of novel drugs and a better understanding of diseases [1]. …

Trend in industry payments to rheumatologists in the United States during the COVID-19 pandemic between 2013 and 2021

A Murayama, S Kamamoto, K Higuchi… - The Journal of …, 2023 - jrheum.org
The Open Payments Database (OPD), the legally binding database of payments made by
pharmaceutical companies and device manufacturers to all physicians, 1 was launched in …

[HTML][HTML] Trend in industry payments to infectious disease physicians in the United States: a seven-year analysis of nonresearch payments from the Open Payments …

A Murayama, K Nakano, S Kamamoto, M Sato… - Clinical Microbiology …, 2022 - Elsevier
Objective To evaluate the trend in nonresearch payments made by the industries to the
infectious disease physicians in the United States since the launch of the Open Payments …

Nature and trends in personal payments made to the respiratory physicians by pharmaceutical companies in Japan between 2016 and 2019

A Murayama, M Hoshi, H Saito, S Kamamoto… - Respiration, 2022 - karger.com
Background: Financial relationships between healthcare professionals and pharmaceutical
companies have historically caused conflicts of interest and unduly influenced patient care. …

Cross-sectional analysis of pharmaceutical payments to Japanese board-certified gastroenterologists between 2016 and 2019

A Murayama, S Kamamoto, M Kawashima, H Saito… - BMJ open, 2023 - bmjopen.bmj.com
Objectives Limited evidence is available regarding the financial relationships between
gastroenterologists and pharmaceutical companies in Japan. This study analysed the magnitude, …

Evaluation of Financial and Nonfinancial Conflicts of Interest and Quality of Evidence Underlying Psoriatic Arthritis Clinical Practice Guidelines: Analysis of Personal …

H Mamada, A Murayama, S Kamamoto… - Arthritis Care & …, 2023 - Wiley Online Library
Objective To assess financial conflicts of interest (COI) and nonfinancial COI among
psoriatic arthritis (PsA) clinical practice guideline (CPG) authors in Japan and the US, and to …

Evaluation of financial relationships between Japanese certified pediatric hematologist/oncologists and pharmaceutical companies: a cross‐sectional analysis of …

S Kamamoto, A Murayama, E Kusumi… - Pediatric Blood & …, 2022 - Wiley Online Library
This cross‐sectional study evaluated the magnitude of personal payments made by
pharmaceutical companies to pediatric hematologist‐oncologists (PHOs) board‐certified by the …